Astrazeneca in cancer drug deal

Drugs giant Astrazeneca is to pay up to $6.9 billion (£5.3bn) to Japan’s Daiichi Sankyo to develop and sell a next-generation cancer treatment. The agreement relates to Daiichi Sankyo’s drug trastuzumab deruxtecan and will see Astrazeneca pay $1.35bn upfront, with further payments linked to sales targets. Daiichi Sankyo will be responsible for manufacturing and supply.